No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma
No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma
AMAROS trial: radiotherapy versus lymph node dissection in breast cancer
Treatment of primary central nervous system germinoma with chemotherapy
Treating peripheral lung tumours with SABR
Diagnosis and treatment in rare cases of thymoma
Treating non-small cell lung cancer with surgery versus SABR
Using chemo-radiotherapy without increasing toxicity
Early effect of PI3K-Akt-mTOR blockade on in vitro 18F-FDG uptake in HER2 breast cancer resistant to trastuzumab
Approaches to treatment of brain metastasis
Closing the cancer divide: Implementing the diagonal approach
Chemo-radiotherapy for bladder cancer
Pelvic radiotherapy and androgen blockade for high risk prostate cancer